1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MSC Industrial said CFO Kristen Actis-Grande will step down effective August 8, 2025, to become CFO of another publicly traded company, and Greg Clark, the company's Vice President of Finance and Corporate Controller, will serve as interim CFO. The company said it will search for a permanent CFO. In the same July 28 release, management said fiscal fourth-quarter results are trending toward the upper half of its prior guidance ranges.
Kristen Actis-Grande resigns as EVP and CFO effective August 8, 2025; the filing says the decision is not due to any disagreement with the company.
Greg Clark, 57, is appointed interim CFO effective August 8, 2025, and has been VP of Finance and Corporate Controller since April 2018.
June average daily sales rose 2.5% year-over-year; fiscal Q4 is trending toward the upper half of guidance of (0.5)% to 1.5% ADS growth and 8.5% to 9.0% adjusted operating margin.
Elevance Health's board elected Steven H. Collis, Executive Chairman of Cencora, as an independent director effective August 1, 2025, with a term expiring at the 2027 annual meeting. He was also appointed to the Audit and Finance Committees, and the board determined he qualifies as an audit committee financial expert. The filing describes a routine board addition with no financial figures disclosed.
Steven H. Collis elected by the board on July 28, 2025, effective August 1, 2025
Term expires at the Company's 2027 annual meeting of shareholders
Appointed to the Audit and Finance Committees; board determined he is an audit committee financial expert
Previously president and CEO of Cencora for 13 years, and became Executive Chairman in 2024
BlackLine, Inc. appointed Gregory Hughes to its Board of Directors effective July 25, 2025, and he will also join the Compensation Committee. Hughes previously served as CEO of Veritas Technologies from 2018 to 2024, and the filing describes him as a director of several public and private companies. The filing reports no financial results, so the appointment is an addition to board governance rather than a change in company performance.
Gregory Hughes appointed to the Board by the Board on July 24, 2025, term beginning July 25, 2025
Hughes will serve in the class of directors whose term expires at the 2027 annual meeting and will join the Compensation Committee
Hughes was CEO and a board member of Veritas Technologies LLC from 2018 to 2024, and has been a board member of Cohesity since the merger
He will receive cash and equity compensation under the Outside Director Compensation Policy and sign the standard indemnification agreement
Entergy's board elected R. Lewis Ropp, a retired Barrow Hanley investment manager, as a director effective August 15, 2025, and increased the board to 11 members. The board deemed him independent and he will sit on the Audit and Corporate Governance Committees, a routine board addition with no financial terms disclosed in the filing.
Board elected R. Lewis Ropp on July 25, 2025, effective August 15, 2025, serving until the 2026 Annual Meeting
Board size increased to 11 members; Ropp deemed independent under NYSE rules
Ropp will join the Audit Committee and Corporate Governance Committee
Compensation matches other non-employee directors, pro-rated from August 15, 2025 to the 2026 Annual Meeting
Bio-Rad Laboratories appointed Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025, succeeding Mike Crowley, who is retiring after a 26-year career with the company. Mehta previously served as Senior Vice President at Labcorp and as Vice President and General Manager at Thermo Fisher Scientific.
Rajat Mehta becomes EVP, Global Commercial Operations, effective August 4, 2025
Mike Crowley, who announced his retirement on January 31, 2025, will no longer be an executive officer and will remain an employee until September 2025 to assist with the transition
Mehta joins from Labcorp, where he was Senior Vice President overseeing commercial operations for the West Division
Zebra Technologies appointed Mary McDowell as a Class I director effective July 25, 2025, raising the board from ten to eleven members. She also joined the Audit Committee, which grew from five to six members. The change adds a director with prior CEO and board experience at technology companies, and the filing discloses no financial results.
Board expanded from ten to eleven directors effective July 25, 2025
McDowell joins the Audit Committee, which grew from five to six members
Class I term expires at the 2027 Annual Meeting of Stockholders
Her compensation will follow the standard non-employee director arrangements, prorated for her start date
Carlyle said John Redett, Mark Jenkins and Jeff Nedelman will become Co-Presidents, and Justin Plouffe will become Chief Financial Officer, all effective January 1, 2026. Redett, the current CFO, will remain in that role through the end of 2025 to ensure a transition, and the filing describes the changes as part of a broader senior leadership reshuffle that also includes Michael Wand and Admiral James Stavridis.
John Redett, Mark Jenkins and Jeff Nedelman become Co-Presidents effective January 1, 2026; Redett will lead Global Private Equity, Jenkins Global Credit and Insurance, and Nedelman will continue leading Global Client Business
Justin Plouffe, currently Deputy Chief Investment Officer for Global Credit, succeeds Redett as Chief Financial Officer effective January 1, 2026
Redett remains CFO through year-end 2025; Michael Wand becomes Head of EMEA Investments and Admiral James Stavridis becomes Vice Chairman, both effective January 1, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.